Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
Supplementary Materials
Supplementary Figure S1 : (A) Progression-free survival (PFS) (4.8 vs. 1.8 months, Log-rank; P < 0.001) and (B) overall survival (OS) (12.0 vs. 9.8 months, Log-rank test, P = 0.104) in patients with metastatic colorectal cancer treated with regorafenib according to VEGF-A levels decreased (Dec) on day 21 followed by increased (Inc) at progressive disease (-Good, n = 10) or the opposite (-Poor, n = 12). 3) 4 (7.4) 1 (1.9) 5 (9.3) ALT increased 14 (25.9) 4 (7.4) 3 (5.6) 1 (1.9) 4 (7.4) T-BIL increased 18 (33.3) 18 (33.3) 3 (5.6) 0 3 (5.6) Thrombocytopenia 16 (29.6) 5 (9.3) 1 (1.9) 1 (1.9) 2 (3.7)
Supplementary
CTCAE, the Common Terminology Criteria for Adverse Events; Gr, grade; HFSR, Hand-foot skin reaction; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-BIL, total bilirubin.
